- Home
- SRZN vs CNTX Comparison
SRZN vs CNTX Comparison
Compare SRZN & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | CNTX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 116.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRZN | CNTX |
|---|---|---|
| Price | $19.67 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.50 | $5.67 |
| AVG Volume (30 Days) | 100.8K | ★ 1.2M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,604,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $0.49 |
| 52 Week High | $24.94 | $2.00 |
Technical Indicators
Market Signals| Indicator | SRZN | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 77.51 |
| Support Level | $21.03 | $1.09 |
| Resistance Level | $23.42 | $2.00 |
| Average True Range (ATR) | 1.84 | 0.16 |
| MACD | -0.60 | 0.06 |
| Stochastic Oscillator | 28.45 | 68.45 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.